Valuation: Gilead Sciences, Inc.

Capitalization 163B 138B 127B 120B 223B 15,409B 225B 1,501B 586B 7,396B 612B 599B 25,547B P/E ratio 2026 *
-150x
P/E ratio 2027 * 17.3x
Enterprise value 170B 144B 132B 125B 233B 16,074B 235B 1,566B 611B 7,715B 638B 625B 26,649B EV / Sales 2026 *
5.6x
EV / Sales 2027 * 5x
Free-Float
99.87%
Yield 2026 *
2.47%
Yield 2027 * 2.53%
1 day-2.04%
1 week-0.24%
Current month+0.37%
1 month-7.21%
3 months-13.88%
6 months+10.51%
Current year+7.00%
1 week 129
Extreme 129
136.75
1 month 127.64
Extreme 127.64
142.38
Current year 116.88
Extreme 116.88
157.29
1 year 96.18
Extreme 96.185
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5d. change 1-year change 3-years change Capi.($)
-2.04%-0.24%+33.79%+67.11% 163B
-2.72%-1.54%+29.12%+121.40% 846B
-0.53%-2.58%+43.51%+37.42% 533B
-0.57%-2.44%+9.18%+37.27% 356B
-0.94%-0.97%+21.32%+10.98% 324B
+0.23%-1.24%+31.68%+11.93% 282B
+0.05%-2.19%+24.42%+20.97% 278B
-0.82%-0.70%+46.61%-5.15% 275B
-1.76%+4.42%-32.32%-49.34% 203B
+0.79%+0.57%+21.93%+41.38% 179B
Average -0.83%-0.69%+22.92%+29.40% 343.89B
Weighted average by Cap. -1.10%-1.22%+26.00%+45.24%

Financials

2026 *2027 *
Net sales 30.4B 25.8B 23.6B 22.31B 41.58B 2,872B 41.97B 280B 109B 1,378B 114B 112B 4,761B 32.25B 27.37B 25.03B 23.66B 44.1B 3,047B 44.52B 297B 116B 1,462B 121B 118B 5,051B
Net income -175M -149M -136M -129M -240M -16.57B -242M -1.61B -630M -7.95B -658M -644M -27.46B 9.41B 7.99B 7.3B 6.91B 12.87B 889B 12.99B 86.62B 33.8B 427B 35.3B 34.56B 1,474B
Net Debt 7.04B 5.97B 5.46B 5.16B 9.62B 665B 9.71B 64.75B 25.27B 319B 26.39B 25.84B 1,102B -1.84B -1.56B -1.43B -1.35B -2.51B -174B -2.54B -16.91B -6.6B -83.28B -6.89B -6.75B -288B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
08/05/26 131.33 $ -2.04% 10,250,367
07/05/26 134.06 $ -1.64% 8,901,045
06/05/26 136.30 $ +2.11% 6,351,160
05/05/26 133.48 $ +0.60% 6,152,431
04/05/26 132.69 $ +0.79% 5,880,732
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
131.33USD
Average target price
158.07USD
Spread / Average Target
+20.36%

Quarterly revenue - Rate of surprise